Progress on treatment of MET signaling pathway in non-small cell lung cancer

被引：0
作者：
Xiaoqing Yu
Sizhe Yu
Yun Fan
机构：
[1] Chinese Academy of Sciences,Institute of Cancer and Basic Medicine (ICBM)
[2] University of Chinese Academy of Sciences,Department of Medical Oncology, Cancer Hospital
[3] Zhejiang Cancer Hospital,Department of Medical Oncology
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
MET; Dysregulation; Overexpression; Amplification; Non-small cell lung cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
MET activation includes gene mutation, amplification, and protein overexpression. Clinical evidence suggests that MET activation is both a primary oncogenic driver in lung cancer, and a secondary driver after acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Several small molecule TKIs have already shown to be effective in the MET pathway. However, the activation form and the diagnostic criteria of MET oncogene are still controversial, especially in patients resistant to EGFR TKIs or ALK TKIs. With the development of new MET inhibitors, a quantity of emerging trials has focused on the mechanism of acquired resistance to MET TKIs and therapeutic strategies after resistance.
引用
收藏
页码：1450 / 1458
页数：8
相关论文
共 124 条
[1]  
Engelman JA(2007)MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 1039-1043
[2]  
Kreshnik Z(2007)MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Proc Natl Acad Sci USA 104 20932-20937
[3]  
Tetsuya M(2010)MET molecular mechanisms and therapies in lung cancer Cell Adh Migr 4 146-152
[4]  
James B(2015)Gene of the month: MET J Clin Pathol 68 405-409
[5]  
Cameron B(2011)An overview of the c-MET signaling pathway Ther Adv Med Oncol 3 S7-81
[6]  
Jin-Yuan S(2016)Targeting MET in lung cancer: will expectations finally be MET? J Thorac Oncol 12 S1556086416311790-1671
[7]  
Lawrence RE(2017)Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? Cancer Treat Rev 61 70-207
[8]  
Salgia R(2019)MET IHC is a poor screen for MET amplification or MET exon 14 mutations in lung adenocarcinomas: data from a tri-institutional cohort of the lung cancer mutation consortium J Thorac Oncol 14 1666-1304
[9]  
Garret S(2012)High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients Histol Histopathol 27 197-94
[10]  
Dhirendra G(2014)MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis PLoS ONE 9 e107677-172
12345678910